Klemetsdal B, Flaegstad T, Aarbakke J
Department of Pharmacology, University of Tromsø, Norway.
Med Pediatr Oncol. 1995 Dec;25(6):445-9. doi: 10.1002/mpo.2950250605.
We have examined red blood cell (RBC) thiopurine methyltransferase (TPMT) activity in a healthy population sample of Norwegian children, age 1-10 years. Boys had mean RBC TPMT activity of 11.1 +/- 2.0 U (n = 87) vs. 10.6 +/- 2.2 U (n = 71) in girls, the difference was not significant (P = 0.3). Age was negatively correlated to RBC TPMT activity (rs = -0.2, P = 0.01). As boys with acute lymphoblastic leukemia (ALL) tolerate more 6-mercaptopurine (6-MP) than girls and have a higher risk of relapse, we have searched for pharmacokinetic causes of these gender differences. The gender difference in 6-MP tolerance and clinical outcome in children with ALL cannot be explained by the minor and nonsignificant higher RBC TPMT activity in boys compared to girls.
我们检测了挪威1至10岁健康儿童群体样本中的红细胞(RBC)硫嘌呤甲基转移酶(TPMT)活性。男孩的平均RBC TPMT活性为11.1±2.0 U(n = 87),而女孩为10.6±2.2 U(n = 71),差异不显著(P = 0.3)。年龄与RBC TPMT活性呈负相关(rs = -0.2,P = 0.01)。由于患有急性淋巴细胞白血病(ALL)的男孩比女孩能耐受更多的6-巯基嘌呤(6-MP)且复发风险更高,我们探究了这些性别差异的药代动力学原因。ALL患儿中6-MP耐受性和临床结局的性别差异无法用男孩相比女孩略高且无显著意义的RBC TPMT活性来解释。